Monsanto announced today that it is pursuing a divestiture of its dairy product, POSILAC® bovine somatotropin (commonly known as rBST). Additional details have not been disclosed at this time.
“While POSILAC is a strong product for the business, we believe repositioning the business with a strategic owner will allow Monsanto to focus on the growth of its core seeds and traits business while ensuring that loyal dairy farmers continue to receive the value of POSILAC in their operations,” said Carl Casale, Monsanto’s Executive Vice-President of Strategy and Operations.
POSILAC is an FDA-approved animal pharmaceutical used by U.S. dairy farmers to increase productivity. Since it was first sold in the United States in 1994, POSILAC has become the country’s leading dairy animal supplement. Supplementing dairy cows with POSILAC safely enhances milk production and serves as an important tool to help dairy producers improve the efficiency of their operations and produce more milk more sustainably. POSILAC helps farmers with herds of all sizes produce more milk per cow. This increase in production provides dairy farmers with additional economic security by increasing the return on their overall investment. Cows supplemented with POSILAC produce an average of 10 lb. more milk per day.
A recent study conducted by several researchers at Cornell University highlighted the role of POSILAC as an on-farm dairy tool that can effectively reduce the environmental impact of dairy operations.
We feel POSILAC is an outstanding product for dairy farmers to meet the world’s growing demand for food. POSILAC is a proven tool for increasing dairy cow milk production and profitability. With historically high milk prices, dairy producers who use POSILAC are deriving significant value from their investment.
3 Comments on “Monsanto Looks to Sell Posilac”
Your article pretends there is no controversy about Posilac. It pretends that the drug simply boosts milk production with no increase in mastitus and consequent increase in antibiotic use, and that the cows are fine at the end of their shortened life. Just a tool on the farm, IGF in the milk is not a problem for anyone.
Your article pretends there is no controversy about Posilac. It pretends that the drug simply boosts milk production with no increase in mastitus and consequent increase in antibiotic use, and that the cows are fine at the end of their shortened life. Just a tool on the farm, IGF in the milk is not a problem for anyone.
Your article pretends there is no controversy about Posilac. It pretends that the drug simply boosts milk production with no increase in mastitus and consequent increase in antibiotic use, and that the cows are fine at the end of their shortened life. Just a tool on the farm, IGF in the milk is not a problem for anyone.